The Genesis of Tonic Easy Medical: From Clinical Frustration to a 200,000-Doctor Platform

Daniela Seixas never planned to be an entrepreneur. A neuro-radiologist by training, she grew frustrated during her clinical work at Hospital de S. João in Porto because referring a stroke patient meant up to 30 minutes of phone calls to pass on critical information—time that can determine whether a person walks or speaks again. That irritation seeded Tonic App, a secure messaging tool for doctors that launched in 2015 and formalised a year later with three co-founders from her IE Business School MBA.

The platform quickly moved beyond communication. It now offers clinical decision trees, treatment algorithms, medical quizzes, a jobs board, and, most critically, an AI-powered clinical copilot that supports pharmacological decision-making. In 2025, that copilot received certification as a medical device, making Tonic one of the first European companies to secure such a mark for clinical AI. The startup counts roughly 200,000 doctors on its platform, with 57% of all Portuguese doctors and 70% of family physicians actively using it. Italy is its fastest-growing market, already hosting over 85,000 registered doctors.

Funding has tracked this expansion. A first round of €500,000 came from Portugal Ventures in 2017; a €3.5 million round followed in 2019 with Vesalius Biocapital Partners and Armilar Venture Partners. By 2024 the company had raised another €10 million, bringing total venture capital to over €20 million. A further round is in final negotiations, intended to fuel entry into the UK and Germany—the two markets Seixas sees as essential to becoming the European leader within two years.

Where Tonic Sits in the Health Tech Landscape and What Its AI Certification Means

A Business Model Built on Pharma Partnerships, Not Doctor Fees

Tonic’s revenue does not come from charging physicians; the platform remains free for medical professionals. Instead, it acts as a curated bridge between doctors and life sciences companies—16 major pharmaceutical firms, including Novartis, Roche, Pfizer, AstraZeneca and MSD, work with Tonic to deliver product information under rules set by the startup’s own medical team. This model creates a high-margin, sticky service: pharma gets targeted, compliant outreach to an engaged physician base, and doctors receive clinically relevant updates without advertising noise. The risk is concentration on a limited client list, but the high penetration rate among Portuguese GPs and the rapid Italian growth give Tonic credible metrics to expand that roster.

Advertisement

Competitive Moat: From Communication Tool to Certified AI Device

Seixas says the platform faces “practically no competition in its niche,” and the early 2025 AI medical device certification strengthens that claim. Few European health tech startups have achieved Class IIa/IIb certification for a generative AI decision-support tool, which acts as both a regulatory shield and a selling point when entering markets like Germany and the UK with strict medical software rules. The copilot, built in-house under Chief AI Officer João Guichard, has already quadrupled usage in two years. Its real competitive value, however, lies in the clinical data it could accumulate if usage keeps climbing—data that can refine algorithms and deepen the platform’s lock-in with hospitals and physicians.

Scaling Headaches: Different Healthcare Systems, One Platform

Leading “the European market” is not a single market but a patchwork of national health services, regulatory bodies, languages, and purchasing processes. Tonic is present in Spain, France and Italy, yet the UK and Germany represent a step change in complexity. Each country requires localized clinical content, data residency compliance, and relationships with national pharma branches. The upcoming funding round—still not closed—must cover these fixed costs before any revenue materialises. On the plus side, starting in a small domestic market forced international thinking from day one, and the company’s 67% female workforce may offer a cultural advantage in hiring across borders where talent competition is fierce.

What the Next Funding Round and European Push Require from Tonic’s Leadership

  • Use the AI device certification as the spearhead for German and UK entry. Regulators in both countries demand rigorous evidence of clinical safety and benefit. The CE-marked device provides pre-packaged credibility that can shorten sales cycles with hospital procurement teams.
  • Deepen pharma relationships beyond top 16 clients. The current model depends heavily on a handful of multinationals. Tonic needs to convert its 200,000-doctor base into a broader portfolio of smaller pharma and medtech firms, especially as it moves into markets where local champions matter.
  • Resource local legal and medical affairs teams for each new country from day one. The platform’s data protection, promotional content, and device registration requirements change at every border. Underfunding compliance early would risk delays that competitors could exploit.
  • Lock in physician engagement with tools that create daily workflow habits. The copilot’s rising usage suggests that embedding AI clinical support into routine patient care can make the platform indispensable—a dynamic the company should nurture with co-development projects at major hospitals in target countries.
  • Prepare for heightened scrutiny on the pharma-funding model. As Tonic becomes more visible, European healthcare watchdogs may examine the separation between editorial medical information and commercial promotion. Proactively publishing transparency reports on partnerships could pre-empt regulatory friction.

Risk & Opportunity Assessment

Commercial RiskMediumRevenue depends on a limited number of large pharmaceutical clients. A single client reducing spend or shifting to competitor platforms could materially impact income, and the upcoming round is not yet closed, creating funding uncertainty.
Competitive RiskLowTonic operates in a narrow niche—secure communication plus AI clinical support—with a self-described absence of direct competition. However, larger health tech ecosystems could integrate similar features, raising the risk if Tonic fails to execute its European expansion quickly.
Regulatory RiskHighExpansion into the UK and Germany requires navigating distinct medical device regulations, data privacy laws, and rules on pharmaceutical communication. The AI copilot’s certification as a medical device in one jurisdiction does not automatically transfer; re-certification or additional approvals will be required.
Reputation RiskLowThe founder has a strong professional reputation, and the company has maintained a clinician-first image. Any breach of data security on a platform handling patient-related communication could cause reputational damage, but no incidents have been reported.
Technology DisruptionHighThe generative AI field is evolving rapidly. Large language models from global tech companies could offer free or integrated clinical support tools that erode Tonic’s copilot advantage. Continuous investment in proprietary data and clinical validation is essential to defend against this disruption.
Commercial OpportunityHighWith 200,000 doctors already on the platform and a certified AI medical device, Tonic is well positioned to capture a significant share of the European digital health support market. The planned entry into the UK and Germany—large pharmaceutical markets—multiplies revenue potential if the model transfers successfully.